SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study).
Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer
Langer, Corey J CJ; Redman, Mary W MW; Wade, James L JL; Aggarwal, Charu C; Bradley, Jeffrey D JD; Crawford, Jeffrey J; Stella, Philip J PJ; Knapp, Mark H MH; Miao, Jieling J; Minichiello, Katherine K; Herbst, Roy S RS; Kelly, Karen K; Gandara, David R DR; Papadimitrakopoulou, Vassiliki A VA
Assessing the clinical value of targeted massively parallel sequencing in a longitudinal, prospective population-based study of cancer patients.
British Journal Of Cancer
Wong, S Q SQ; Fellowes, A A; Doig, K K; Ellul, J J; Bosma, T J TJ; Irwin, D D; Vedururu, R R; Tan, A Y-C AY; Weiss, J J; Chan, K S KS; Lucas, M M; Thomas, D M DM; Dobrovic, A A; Parisot, J P JP; Fox, S B SB
Publication Date: 2015-04-14
Variant appearance in text: PIK3CA: 3139C>A; His1047Asn
Tongue carcinoma infrequently harbor common actionable genetic alterations.
Bmc Cancer
Tan, Daniel S W DS; Wang, Weining W; Leong, Hui Sun HS; Sew, Pui Hoon PH; Lau, Dawn P DP; Chong, Fui Teen FT; Krisna, Sai Sakktee SS; Lim, Tony K H TK; Iyer, N Gopalakrishna NG